Peutz-Jeghers syndrome overview: Difference between revisions
No edit summary |
No edit summary |
||
| Line 20: | Line 20: | ||
==Screening== | ==Screening== | ||
Screening for cancerous lesions by small intestine radiography, [[esophagogastroduodenoscopy]] (EGD), [[colonoscopy]], pancreatic [[ultrasound]], pelvic ultrasound, [[mammography]], and Papanicolaou (Pap) test are recommended among patients with Peutz-Jeghers syndrome. | Screening for cancerous lesions by small intestine radiography, [[esophagogastroduodenoscopy]] (EGD), [[colonoscopy]], pancreatic [[ultrasound]], pelvic ultrasound, [[mammography]], and Papanicolaou (Pap) test are recommended among patients with Peutz-Jeghers syndrome. | ||
==Natural History, Complications and Prognosis== | |||
If left untreated, patients with Peutz-Jeghers syndrome may progress to develop rectal bleeding, [[anemia]], [[intussusception]], bowel obstruction, and abdominal pain. Common complications of Peutz-Jeghers syndrome include [[colon cancer]], and [[cachexia]].<ref>Zbuk KM, Eng C. Hamartomatous polyposis syndromes. Nat Clin Pract Gastroenterol Hepatol. 2007 Sep. 4(9):492-502.</ref> | |||
Prognosis is generally good if [[polypectomy]] was performed before any dysplastic degenerations take place. | |||
== References == | == References == | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 02:33, 16 September 2015
|
Peutz-Jeghers syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Peutz-Jeghers syndrome overview On the Web |
|
American Roentgen Ray Society Images of Peutz-Jeghers syndrome overview |
|
Risk calculators and risk factors for Peutz-Jeghers syndrome overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
Peutz-Jeghers, also known as Hereditary Intestinal Polyposis Syndrome, is an autosomal dominant genetic disorder characterized by the appearance of multiple benign hamartomatous polyps in the gastrointestinal tract, which increase the risk of cancer in the gastrointestinal tract. It's also associated with hyperpigmented macules on the lips and oral mucosa (melanosis). The incidence of Peutz–Jeghers syndrome is approximately 1 in 25,000 to 300,000 births.
Historical Perspective
In 1998, STK11 (LKB1) mutations were first identified in the pathogenesis of peutz-Jeghers syndrome. The syndrome is named after Jans Peutz (1886-1957), a Dutch physician and Harold Jeghers (1904-1990), an American physician who had successively described the association between polyposis and the mucocutaneous macules.
Pathophysiology
Peutz-Jeghers syndrome is transmitted in autosomal dominant pattern.
Causes
Peutz-Jeghers syndrome is caused by a mutation in the STK11 (LKB1) tumor suppressor gene.[1]
Differentiating Peutz-Jeghers Syndrome from other Diseases
Peutz-Jeghers syndrome must be differentiated from other diseases that cause hamartomatous polyps and mucocutaneous pigmentation, such as Cowden syndrome, Bannayan–Riley–Ruvalcaba syndrome, and juvenile polyposis.
Epidemiology and Demographics
The incidence of Peutz-Jeghers syndrome is approximately 0.03 to 4 per 100,000 individuals worldwide.
Risk Factors
Common risk factors in the development of Peutz-Jeghers syndrome are mutation in STK11 (LKB1) gene and family history of Peutz-Jeghers syndrome.
Screening
Screening for cancerous lesions by small intestine radiography, esophagogastroduodenoscopy (EGD), colonoscopy, pancreatic ultrasound, pelvic ultrasound, mammography, and Papanicolaou (Pap) test are recommended among patients with Peutz-Jeghers syndrome.
Natural History, Complications and Prognosis
If left untreated, patients with Peutz-Jeghers syndrome may progress to develop rectal bleeding, anemia, intussusception, bowel obstruction, and abdominal pain. Common complications of Peutz-Jeghers syndrome include colon cancer, and cachexia.[2] Prognosis is generally good if polypectomy was performed before any dysplastic degenerations take place.